Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Other hematologic neoplasm 2Gynecologic 2Sarcoma 1Other solid neoplasm 1Lymphoid 1CNS 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

Cisplatin 28Irinotecan 18Gemcitabine 18Paclitaxel 14alvocidib 13Fluorouracil 11Oxaliplatin 10Cyclophosphamide 10Carboplatin 10Leucovorin 8Bortezomib 8Biopsy 8Taxes 7Radiotherapy 7Pemetrexed 7Magnetic Resonance Spectroscopy 7Doxorubicin 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7Specimen Handling 6tanespimycin 5Vorinostat 5LMB-100 5Early Intervention, Educational 5Bevacizumab 5temsirolimus 4sargramostim 4Sorafenib 4Sirolimus 4Platinum 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × trioctyl phosphine oxide × Other solid neoplasm × Clear all
NCT00068484 2013-02-01

A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡